Goodbye Wave: Takeda axes Huntington’s pact, freeing partner to pursue fresh pact

Takeda is walking away from the last target in a collaboration with Wave Life Sciences into which the Japanese pharma has already sunk $260 million over the past six years. The decision leaves Wave holding a Huntington’s disease program that it says has caught the attention of other drug developers.